Stoke Therapeutics (STOK) Common Equity (2018 - 2026)

Stoke Therapeutics' Common Equity history runs 9 years deep, the most recent figure standing at $394.9 million for Q1 2026.

• On a quarterly basis, Common Equity rose 12.8% year-over-year to $394.9 million in Q1 2026; TTM through Mar 2026 was $394.9 million, a 12.8% increase from a year earlier, with the FY2025 full-year figure at $352.5 million, up 53.9% from the prior year.
• Common Equity advanced to $394.9 million in Q1 2026 per STOK's latest filing, from $352.5 million in the prior quarter.
• Across five years, Common Equity topped out at $394.9 million in Q1 2026 and bottomed at $140.3 million in Q1 2024.
• The 5-year median for Common Equity is $229.0 million (2024), against an average of $245.6 million.
• Across the five-year window, Common Equity slumped 34.37% in 2024 and soared 149.44% in 2025, its largest moves.
• Year by year, Common Equity stood at $184.8 million in 2022, then retreated by 13.68% to $159.6 million in 2023, then surged by 43.53% to $229.0 million in 2024, then surged by 53.9% to $352.5 million in 2025, then advanced by 12.04% to $394.9 million in 2026.
• Per Business Quant, the three latest STOK Common Equity figures stand at $394.9 million (Q1 2026), $352.5 million (Q4 2025), and $308.1 million (Q3 2025).